Harbour BioMed GenAI powered HCAb model redefines biologic discovery with faster, smarter, and fully human antibody design.
Harbour BioMed has launched its first GenAI HCAb (Heavy Chain-Only Antibody) Model, built on its Hu-mAtrIx AI platform. The innovation creates a closed-loop discovery system combining AI-driven design, automated screening, and lab validation. The goal is to speed up the creation of next-generation biologics by moving from random screening to precision-driven discovery.
Traditional antibody discovery struggles with the complexity and instability of human VH domains, especially without light-chain pairing. Using GenAI trained on nine million HCAb sequences, Harbour’s model generates novel, functional HCAb structures that maintain stability and specificity. A protein large language model refines these sequences for target affinity before AI-based screening predicts their developability. Evaluating solubility, stability, and aggregation risk. Only the strongest candidates proceed to lab testing.
This GenAI approach has transformed results. The HCAb model achieved a tenfold boost in candidate generation and produced 78.5% successful binders in early validation. Twenty AI-designed molecules demonstrated high yield, nanomolar-level binding affinity, and strong cross-species activity. The outcome is a faster, more predictable path to viable therapeutics. Reducing time from concept to lab validation from months to weeks.
Harbour BioMed’s AI system operates as a self-learning loop, where lab data continuously refine the model. This allows adaptive molecular generation across antibody formats, supporting new therapeutics like bispecifics, ADCs, and CAR-T. The company’s Global AI + Pharmaceutical Ecosystem Alliance expands this approach across biotech, linking AI partners to reshape how biologics are discovered and scaled.
